Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.

You may also be interested in...

Nycomed US Plans Growth Through Acquisition

Now that Takeda has entered into a $13 billion deal to buy Nycomed, the U.S. affiliate, which isn't part of the deal, plans to grow sales by 10% annually through 2015.

Japan's Takeda Reportedly Offering $12B For Europe's Nycomed

The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts